Trial Profile

A Phase I/II, Multicenter, Open-Label, Dose-Escalation and Extension Study of GQ1010(an Anti-Trop2 ADC) in Subjects With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BHV 1510 (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; HER2 negative breast cancer; Male breast cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Suzhou GeneQuantum Healthcare

Most Recent Events

05 Feb 2025 Planned number of patients changed from 220 to 260.
20 Jun 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com